Company Overview of Neocrin Company
As of August 1999, Neocrin Company was acquired by Novocell, Inc. Neocrin Company researches and develops minimally invasive, encapsulated cellular transplants for the treatment of diabetes. Neocrin's technology consists of proprietary immunoprotective cell encapsulation materials and cell purification techniques that the company believes will make it possible to inject insulin-producing, porcine-derived pancreatic cells (islets) into the peritoneal cavity without chronic immunosuppression, to provide near-normal blood glucose control by naturally regulating insulin release. Neocrin Company was founded by Mr. Wes Farrell in 1992. It is headquartered in Irvine, California.
31 Technology Drive
Irvine, CA 92618
Founded in 1992
Key Executives for Neocrin Company
Neocrin Company does not have any Key Executives recorded.
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Neocrin Company, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.